SPOTLIGHT -
Developing Cell Therapy for Progressive MS: Jakob Dupont, MD, MA
The head of global research and executive vice president of Atara Biotherapeutics discussed the upcoming study evaluating ATA188.
ATA188’s Potential in Progressive MS: Jakob Dupont, MD, MA
The head of global research and executive vice president of Atara Biotherapeutics discussed improvements seen in patients treated with the investigational therapy.
Evaluating ATA188 in Progressive MS: Jakob Dupont, MD, MA
The head of global research and executive vice president of Atara Biotherapeutics discussed the trial design of part 2 of the study of ATA188.
Jakob Dupont, MD: Phase 1 Data on Cell Therapy for Progressive MS
The executive vice president and head of global research and development at Atara Biotherapeutics spoke to the findings of a phase 1 study of the cell therapy ATA188.
